Overview

Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This study proposes to evaluate the safety and efficacy of an anti-PD-L1 (durvalumab) agent as neoadjuvant therapy in patients diagnosed with localized NSCLC who are planned to undergo radical RT or CRT. The hypothesis to be tested for the primary objective is that the treatment of durvalumab followed by RT/CRT will be safe and well tolerated in subjects with NSCLC.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Instituto Portugues de Oncologia, Francisco Gentil, Porto

Collaborator:

AstraZeneca

Treatments:

Durvalumab